Billy Evans' Biotech Ambitions and Documentary Fallout

Key points

• Billy Evans, 34, is the father of Holmes's two children and is currently raising them in Austin, Texas, while Holmes serves an 11-year federal sentence in Bryan.
• Evans founded Haemanthus, a biotech startup using laser technology for diagnostic testing, which critics compare to the failed model of Theranos, though Holmes's name is not in the incorporation documents.
• The documentary 'You Can See Everything' has become a box office phenomenon, with over 2,000 sold-out shows and strong preview numbers, despite Evans's attempts to control the narrative.
• Evans and Holmes hoped the film would change public perception, but Evans has since admitted participating may have been a mistake due to the intense backlash and his strained relationship with the filmmakers.
• Holmes is scheduled to transfer to a halfway house in Del Valle, Texas, in August 2027, with her full release date advanced to February 2030.

Background

Our earlier coverage noted that Evans has faced intense scrutiny over Haemanthus, with critics labeling it 'Theranos 2.0.' Previous reports also highlighted that Evans defended the documentary on the 'All-In' podcast, arguing it allowed the public to form independent opinions, even as he acknowledged Holmes appeared 'insane' in the trailer. The documentary, which documents the 34 days before Holmes's imprisonment, has received critical acclaim but intensified public distrust.

How outlets are covering it

The Los Angeles Times emphasizes Evans's controversial role in the documentary, noting his attempts to control the project and his admission that participating may have been a mistake. The New York Times highlights the documentary's box office success, with over 2,000 sold-out shows, and its potential to make Oscars history. Vulture focuses on the director Lance Oppenheim's approach, describing the film as a 'shockingly intimate probe' of Holmes's beliefs. Deadline provides box office data, noting the documentary's strong preview numbers and its potential to outstrip previous documentary records. The outlets differ in their focus: the LA Times and Vulture emphasize the personal and creative dynamics, while the NYT and Deadline focus on the commercial success and cultural impact.

Why it matters

The story highlights the ongoing public fascination with Elizabeth Holmes and the Theranos scandal, as well as the challenges faced by those attempting to rehabilitate a convicted fraudster's image. Evans's new startup and the documentary's success underscore the complex interplay between personal redemption, public perception, and commercial success in the tech and media industries.

What to watch

Holmes is expected to transfer to a halfway house in Del Valle, Texas, in August 2027. Evans will continue to raise their children and pursue Haemanthus, which has raised millions but has yet to release a commercial product. The documentary's box office performance and potential Oscar nomination will likely continue to draw attention to the Holmes-Evans narrative.